Marker Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

31 Mar 2025

MRKR

10-K: Marker Therapeutics Reports 2024 Results, Highlights Progress in Lymphoma and Pancreatic Cancer Trials

Marker Therapeutics' 2024 10-K filing details the company's financial status, clinical trial progress, and strategic shifts, including focusing on MT-601 for lymphoma and pancreatic cancer and MT-401-OTS for AML and MDS.

NASDAQ

25 Mar 2024

MRKR

Marker Therapeutics, INC

10-K: Marker Therapeutics 10-K Filing: Focus on MultiTAA T-Cell Therapies and Strategic Manufacturing Shift

Marker Therapeutics' 10-K filing highlights its clinical-stage immuno-oncology focus on multiTAA-specific T-cell therapies, a strategic shift in manufacturing, and ongoing clinical trials for lymphoma, pancreatic cancer, and AML.